Cargando…

Immunological status of peripheral blood is associated with prognosis in patients with bone and soft-tissue sarcoma

Immune-checkpoint inhibitors have shown promising antitumor effects against certain types of cancer. However, specific immune-checkpoint inhibitors for patients with sarcoma have yet to be identified, whereas the immunological status of peripheral blood in patients with bone sarcoma and soft-tissue...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Youngji, Kobayashi, Eisuke, Suehara, Yoshiyuki, Ito, Ayumu, Kubota, Daisuke, Tanzawa, Yoshikazu, Endo, Makoto, Nakatani, Fumihiko, Nakatsura, Tetsuya, Kawai, Akira, Kaneko, Kazuo, Kitano, Shigehisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7836390/
https://www.ncbi.nlm.nih.gov/pubmed/33510813
http://dx.doi.org/10.3892/ol.2021.12473
_version_ 1783642739240337408
author Kim, Youngji
Kobayashi, Eisuke
Suehara, Yoshiyuki
Ito, Ayumu
Kubota, Daisuke
Tanzawa, Yoshikazu
Endo, Makoto
Nakatani, Fumihiko
Nakatsura, Tetsuya
Kawai, Akira
Kaneko, Kazuo
Kitano, Shigehisa
author_facet Kim, Youngji
Kobayashi, Eisuke
Suehara, Yoshiyuki
Ito, Ayumu
Kubota, Daisuke
Tanzawa, Yoshikazu
Endo, Makoto
Nakatani, Fumihiko
Nakatsura, Tetsuya
Kawai, Akira
Kaneko, Kazuo
Kitano, Shigehisa
author_sort Kim, Youngji
collection PubMed
description Immune-checkpoint inhibitors have shown promising antitumor effects against certain types of cancer. However, specific immune-checkpoint inhibitors for patients with sarcoma have yet to be identified, whereas the immunological status of peripheral blood in patients with bone sarcoma and soft-tissue sarcoma (STS) remains unknown. In addition, it is unclear whether the immunological status from the peripheral blood could be used as a prognostic indicator. Therefore, the present study aimed to clarify the immunological status of peripheral blood samples derived from patients with bone sarcoma and STS. Immune monitoring was performed using the peripheral blood samples of 61 patients with no metastasis of high-grade sarcoma. A total of 25 patients with metastatic sarcoma were used for comparison. A total of 41 immune cell subsets were analyzed using multicolor-flow cytometry. The patients that did not have metastasis demonstrated higher quantities of monocytic myeloid-derived suppressor cells (M-MDSCs) and T cell immunoglobulin and mucin domain-3 (Tim-3)(+) CD8(+) T cells, which were significantly associated with poor disease-free survival (DFS) time, while higher quantities of NKG2D(+) CD8(+) T cells were significantly associated with improved DFS time. Multivariate Cox regression analysis demonstrated that the number of Tim-3(+) CD8(+) T cells was associated with lower DFS time. A significant association was also found between the number of M-MDSCs and progression-free survival (PFS) time in patients with metastasis. The results suggested the occurrence of immune surveillance, which indicated that the host immune reaction against cancer existed in patients with bone sarcoma and STS. Notably, a high number of M-MDSCs was associated with both DFS and PFS time, suggesting a strong prognostic value. The data suggested that the immune status of peripheral blood was associated with the prognosis in patients with sarcoma, as previously reported in patients with other cancer types. In summary, the results may assist with the development of novel strategies for sarcoma treatment, based on the use of biomarkers or immunotherapy.
format Online
Article
Text
id pubmed-7836390
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-78363902021-01-27 Immunological status of peripheral blood is associated with prognosis in patients with bone and soft-tissue sarcoma Kim, Youngji Kobayashi, Eisuke Suehara, Yoshiyuki Ito, Ayumu Kubota, Daisuke Tanzawa, Yoshikazu Endo, Makoto Nakatani, Fumihiko Nakatsura, Tetsuya Kawai, Akira Kaneko, Kazuo Kitano, Shigehisa Oncol Lett Articles Immune-checkpoint inhibitors have shown promising antitumor effects against certain types of cancer. However, specific immune-checkpoint inhibitors for patients with sarcoma have yet to be identified, whereas the immunological status of peripheral blood in patients with bone sarcoma and soft-tissue sarcoma (STS) remains unknown. In addition, it is unclear whether the immunological status from the peripheral blood could be used as a prognostic indicator. Therefore, the present study aimed to clarify the immunological status of peripheral blood samples derived from patients with bone sarcoma and STS. Immune monitoring was performed using the peripheral blood samples of 61 patients with no metastasis of high-grade sarcoma. A total of 25 patients with metastatic sarcoma were used for comparison. A total of 41 immune cell subsets were analyzed using multicolor-flow cytometry. The patients that did not have metastasis demonstrated higher quantities of monocytic myeloid-derived suppressor cells (M-MDSCs) and T cell immunoglobulin and mucin domain-3 (Tim-3)(+) CD8(+) T cells, which were significantly associated with poor disease-free survival (DFS) time, while higher quantities of NKG2D(+) CD8(+) T cells were significantly associated with improved DFS time. Multivariate Cox regression analysis demonstrated that the number of Tim-3(+) CD8(+) T cells was associated with lower DFS time. A significant association was also found between the number of M-MDSCs and progression-free survival (PFS) time in patients with metastasis. The results suggested the occurrence of immune surveillance, which indicated that the host immune reaction against cancer existed in patients with bone sarcoma and STS. Notably, a high number of M-MDSCs was associated with both DFS and PFS time, suggesting a strong prognostic value. The data suggested that the immune status of peripheral blood was associated with the prognosis in patients with sarcoma, as previously reported in patients with other cancer types. In summary, the results may assist with the development of novel strategies for sarcoma treatment, based on the use of biomarkers or immunotherapy. D.A. Spandidos 2021-03 2021-01-18 /pmc/articles/PMC7836390/ /pubmed/33510813 http://dx.doi.org/10.3892/ol.2021.12473 Text en Copyright: © Kim et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Kim, Youngji
Kobayashi, Eisuke
Suehara, Yoshiyuki
Ito, Ayumu
Kubota, Daisuke
Tanzawa, Yoshikazu
Endo, Makoto
Nakatani, Fumihiko
Nakatsura, Tetsuya
Kawai, Akira
Kaneko, Kazuo
Kitano, Shigehisa
Immunological status of peripheral blood is associated with prognosis in patients with bone and soft-tissue sarcoma
title Immunological status of peripheral blood is associated with prognosis in patients with bone and soft-tissue sarcoma
title_full Immunological status of peripheral blood is associated with prognosis in patients with bone and soft-tissue sarcoma
title_fullStr Immunological status of peripheral blood is associated with prognosis in patients with bone and soft-tissue sarcoma
title_full_unstemmed Immunological status of peripheral blood is associated with prognosis in patients with bone and soft-tissue sarcoma
title_short Immunological status of peripheral blood is associated with prognosis in patients with bone and soft-tissue sarcoma
title_sort immunological status of peripheral blood is associated with prognosis in patients with bone and soft-tissue sarcoma
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7836390/
https://www.ncbi.nlm.nih.gov/pubmed/33510813
http://dx.doi.org/10.3892/ol.2021.12473
work_keys_str_mv AT kimyoungji immunologicalstatusofperipheralbloodisassociatedwithprognosisinpatientswithboneandsofttissuesarcoma
AT kobayashieisuke immunologicalstatusofperipheralbloodisassociatedwithprognosisinpatientswithboneandsofttissuesarcoma
AT sueharayoshiyuki immunologicalstatusofperipheralbloodisassociatedwithprognosisinpatientswithboneandsofttissuesarcoma
AT itoayumu immunologicalstatusofperipheralbloodisassociatedwithprognosisinpatientswithboneandsofttissuesarcoma
AT kubotadaisuke immunologicalstatusofperipheralbloodisassociatedwithprognosisinpatientswithboneandsofttissuesarcoma
AT tanzawayoshikazu immunologicalstatusofperipheralbloodisassociatedwithprognosisinpatientswithboneandsofttissuesarcoma
AT endomakoto immunologicalstatusofperipheralbloodisassociatedwithprognosisinpatientswithboneandsofttissuesarcoma
AT nakatanifumihiko immunologicalstatusofperipheralbloodisassociatedwithprognosisinpatientswithboneandsofttissuesarcoma
AT nakatsuratetsuya immunologicalstatusofperipheralbloodisassociatedwithprognosisinpatientswithboneandsofttissuesarcoma
AT kawaiakira immunologicalstatusofperipheralbloodisassociatedwithprognosisinpatientswithboneandsofttissuesarcoma
AT kanekokazuo immunologicalstatusofperipheralbloodisassociatedwithprognosisinpatientswithboneandsofttissuesarcoma
AT kitanoshigehisa immunologicalstatusofperipheralbloodisassociatedwithprognosisinpatientswithboneandsofttissuesarcoma